ImmunityBio (IBRX) Receivables (2014 - 2026)

ImmunityBio (IBRX) has 8 years of Receivables data on file, last reported at $43.3 million in Q1 2026.

• Quarterly Receivables rose 147.95% year-over-year to $43.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.3 million (up 147.95% YoY) and the FY2025 annual result came in at $42.6 million, up 1564.73% from the prior year.
• Receivables advanced to $43.3 million in Q1 2026 per IBRX's latest filing, from $42.6 million in the prior quarter.
• Across five years, Receivables topped out at $43.3 million in Q1 2026 and bottomed at $2.0 million in Q4 2023.
• The 5-year median for Receivables is $3.2 million (2023), against an average of $13.9 million.
• The widest annual swing landed in 2023, when Receivables plunged 36.71%; it then surged 1564.73% in 2025.
• Tracing IBRX's Receivables over 5 years: stood at $3.2 million in 2022, then sank by 36.71% to $2.0 million in 2023, then grew by 26.8% to $2.6 million in 2024, then surged by 1564.73% to $42.6 million in 2025, then rose by 1.54% to $43.3 million in 2026.
• Per Business Quant, the three latest IBRX Receivables figures stand at $43.3 million (Q1 2026), $42.6 million (Q4 2025), and $32.0 million (Q3 2025).

Peer Comparison